Abstract

DESIGN:INTERVENTION TRIAL.PURPOSE:EFFICACY OF 2 RANIBIZUMAB DOSES (0.125 MG/0.25 MG) IN TREATMENT OF AROP.METHODS:34 BABIES RANDOMIZED FOR LOW DOSE [LD] AND CONVENTIONAL DOSE [CD] OF INTRAVITREAL RANIBIZUMAB FOR ZONE 1 A-ROP AND ZONE 2 POST AROP.F/U DONE OVER 1.5 YRS.RESULTS:17 AROP ALLOTED FOR LD AND 16 FOR CD[1 INFANT OF CD DIED].LD APPLIED TO 5 B/E & 4 S/E WITH Z-1 AROP, REST WERE Z-2 POST AROP; 6 B/E & 2 S/E.CD GIVEN TO 5 B/E & 3 S/E OF Z-1 AROP, & 4 B/E & 4 S/E OF Z-2 POST AROP.OF 28 EYES GIVEN LD, 19 HAD COMPLETE VASCULARISATION [35.71% IN Z-1 AROP,ALL IN Z-2 POST AROP]. IN CD, ONLY 4 OF 25 HAD THE SAME. [33% IN Z-2 POST AROP, 0% IN Z-1 AROP]. (p<.05).RECURRENCE WITH LD SEEN IN 21% [ 43% IN Z-1 AROP]; WITH CD IT IS 52%. [62% IN Z-1 AROP AND 42% IN Z-2 POST AROP]. (p<.05).PERSISTANT AVASCULARITY FOUND IN 11% WITH LD [21% OF Z-1 AROP]; 32% IN CD [38% IN Z-1 AROP,25% IN Z-2 POST AROP].
CONCLUSION: LD PROVED SIGNIFICANT IN COMPLETE VASCULARIZATION AND PREVENTION OF RECURRENCE.

Full Text